Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy

Author(s): Jiyang Li, Guangqiang Li, Wenqing Xu

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 14 , 2013

Become EABM
Become Reviewer
Call for Editor


Histone deacetylases are able to catalyze the hydrolysis of N-acetyl lysine residues of histones which package chromosomal DNA. Therefore they play an important role in mediating gene expression and cell proliferation. HDAC inhibitors have not only shown promise as antiparasitic, antineurodegenerative, antirheumatologic agents and immunosuppressant, but as potent anticancer agents by inducing cell cycle arrest, differentiation and apoptosis. This review highlights recent development in design, synthesis and biological evaluation of HDAC inhibitors for cancer therapy.

Keywords: Antitumor drugs, cancer therapy, cyclic peptide, drug discovery, epigenetic regulation, histone deacetylase, hdac isoforms, histone deacetylase inhibitors, hybrid compounds, multi-targeted inhibitor.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 27 March, 2013
Page: [1858 - 1886]
Pages: 29
DOI: 10.2174/0929867311320140005

Article Metrics

PDF: 51